GB0420831D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB0420831D0
GB0420831D0 GB0420831A GB0420831A GB0420831D0 GB 0420831 D0 GB0420831 D0 GB 0420831D0 GB 0420831 A GB0420831 A GB 0420831A GB 0420831 A GB0420831 A GB 0420831A GB 0420831 D0 GB0420831 D0 GB 0420831D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
neurological
processes
preparation
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB0420831A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GB0420831A priority Critical patent/GB0420831D0/en
Publication of GB0420831D0 publication Critical patent/GB0420831D0/en
Priority to DE602005015002T priority patent/DE602005015002D1/de
Priority to AT05789636T priority patent/ATE433966T1/de
Priority to PCT/EP2005/010169 priority patent/WO2006029906A1/en
Priority to EP05789636A priority patent/EP1789410B1/en
Priority to JP2007531711A priority patent/JP2008513405A/ja
Priority to US11/575,311 priority patent/US7638631B2/en
Priority to ES05789636T priority patent/ES2326182T3/es
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Indole Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GB0420831A 2004-09-17 2004-09-17 Novel compounds Ceased GB0420831D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GB0420831A GB0420831D0 (en) 2004-09-17 2004-09-17 Novel compounds
DE602005015002T DE602005015002D1 (de) 2004-09-17 2005-09-16 Methylendipiperidinderivate
AT05789636T ATE433966T1 (de) 2004-09-17 2005-09-16 Methylendipiperidinderivate
PCT/EP2005/010169 WO2006029906A1 (en) 2004-09-17 2005-09-16 Methylene dipiperidine derivatives
EP05789636A EP1789410B1 (en) 2004-09-17 2005-09-16 Methylene dipiperidine derivatives
JP2007531711A JP2008513405A (ja) 2004-09-17 2005-09-16 メチレンジピペリジン誘導体
US11/575,311 US7638631B2 (en) 2004-09-17 2005-09-16 Methylene dipiperidine derivatives
ES05789636T ES2326182T3 (es) 2004-09-17 2005-09-16 Derivados de metilendipiperidina.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0420831A GB0420831D0 (en) 2004-09-17 2004-09-17 Novel compounds

Publications (1)

Publication Number Publication Date
GB0420831D0 true GB0420831D0 (en) 2004-10-20

Family

ID=33306857

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0420831A Ceased GB0420831D0 (en) 2004-09-17 2004-09-17 Novel compounds

Country Status (8)

Country Link
US (1) US7638631B2 (https=)
EP (1) EP1789410B1 (https=)
JP (1) JP2008513405A (https=)
AT (1) ATE433966T1 (https=)
DE (1) DE602005015002D1 (https=)
ES (1) ES2326182T3 (https=)
GB (1) GB0420831D0 (https=)
WO (1) WO2006029906A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
CN103382174A (zh) 2006-06-23 2013-11-06 雅培制药有限公司 作为组胺h3受体调节物的环丙胺衍生物
CA2687931C (en) * 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
HUE025547T2 (en) 2008-12-19 2016-02-29 Boehringer Ingelheim Int Cyclic pyrimidine-4-carboxamides as CCR2 receptor antagonists for the treatment of inflammation, asthma and COPD
US9186353B2 (en) * 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
US20120028931A1 (en) * 2009-09-14 2012-02-02 Recordati Ireland Limited Heterocyclic m-glu5 antagonists
ES2674275T3 (es) 2009-12-17 2018-06-28 Centrexion Therapeutics Corporation Antagonistas del receptor CCR2 y usos de los mismos
AU2011212951A1 (en) * 2010-02-04 2012-08-23 Flsmidth A/S Method for treating tailings
EP2569298B1 (en) 2010-05-12 2015-11-25 Boehringer Ingelheim International GmbH Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011141477A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011144501A1 (en) 2010-05-17 2011-11-24 Boehringer Ingelheim International Gmbh Ccr2 antagonists and uses thereof
EP2576542B1 (en) 2010-05-25 2015-04-22 Boehringer Ingelheim International GmbH Cyclic amide derivatives of pyridazine-3-carboxylic acids and their use in the treatment of pulmonary, pain, immune related and cardiovascular diseases
EP2576538B1 (en) 2010-06-01 2015-10-28 Boehringer Ingelheim International GmbH New CCR2 antagonists
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
EP2731941B1 (en) 2011-07-15 2019-05-08 Boehringer Ingelheim International GmbH Novel and selective ccr2 antagonists
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
EP2647377A1 (en) 2012-04-06 2013-10-09 Sanofi Use of an h3 receptor antagonist for the treatment of alzheimer's disease
MX383744B (es) 2015-07-02 2025-03-14 Centrexion Therapeutics Corp Citrato de (4-((3r,4r)-3-metoxitetrahidro-piran-4-ilamino)piperidin-1-il) (5-metil-6-(((2r, 6s)-6-(p-tolil)tetrahidro-2h-piran-2-il) metilamino) pirimidin-4-il) metanona.
EP3383853B1 (en) 2015-12-01 2020-11-04 Merck Sharp & Dohme Corp. Homobispiperidinyl derivatives as liver x receptor (lxr) beta agonists for treating e.g. alzheimer's disease
WO2025256550A1 (zh) * 2024-06-12 2025-12-18 杭州中美华东制药有限公司 靶向降解剂配体及连接基的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0418071A (ja) 1990-05-11 1992-01-22 Sumitomo Pharmaceut Co Ltd ビスピペリジン誘導体
TR200002182T2 (tr) 1998-01-27 2000-12-21 Aventis Pharmaceuticals Products Inc. İkame edilmiş aksozaherosayklil faktör xa inhibitörleri
AP2005003199A0 (en) 1999-04-01 2005-03-31 Pfizer Prod Inc Aminopyrimidines as sorbitol dehydrogenase inhibitors
SK1182002A3 (en) 1999-07-28 2002-11-06 Aventis Pharm Prod Inc Substituted oxoazaheterocyclyl compounds
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
BR0115783A (pt) 2000-11-30 2003-09-16 Pfizer Prod Inc Combinação de agonistas de gaba e inibidores de sorbitol desidrogenase
AU2002253929A1 (en) 2001-02-08 2002-09-24 Schering Corporation Use of dual h3/m2 antagonists with a bipiperidinic structure in the treatment of cognition deficit disorders
US6660858B2 (en) 2001-03-28 2003-12-09 Lion Bioscience Ag 2-aminobenzoxazole derivatives and combinatorial libraries thereof
US6956040B2 (en) * 2001-07-16 2005-10-18 Ranbaxy Laboratories Limited Oxazolidinone piperazinyl derivatives as potential antimicrobials
EP2243776A1 (en) 2001-10-12 2010-10-27 High Point Pharmaceuticals, LLC Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor

Also Published As

Publication number Publication date
ES2326182T3 (es) 2009-10-02
WO2006029906A1 (en) 2006-03-23
EP1789410B1 (en) 2009-06-17
US20080108624A1 (en) 2008-05-08
EP1789410A1 (en) 2007-05-30
DE602005015002D1 (de) 2009-07-30
JP2008513405A (ja) 2008-05-01
US7638631B2 (en) 2009-12-29
ATE433966T1 (de) 2009-07-15

Similar Documents

Publication Publication Date Title
TW200500344A (en) Novel compounds
TW200503713A (en) Novel compounds
GB0420831D0 (en) Novel compounds
TW200503710A (en) Novel compounds
GB0329214D0 (en) Novel compounds
TW200621716A (en) Novel compounds
TW200514781A (en) Novel compounds
MY138836A (en) Quinoline derivatives and their use as 5-ht6 receptor ligands
TW200531689A (en) Therapeutic agents
WO2005004818A3 (en) Heterocyclic compounds and their use as anticancer agents
GB0625648D0 (en) Compounds
GB0111186D0 (en) Novel compounds
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200611702A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
CR9622A (es) Derivados de pirazolo[3,4-d]azepina como antagonistas de histamina h3
TW200611701A (en) Novel compounds
IL185869A0 (en) Fused thiazole derivatives having affinity for the histamine h3 receptor
GB0320320D0 (en) Novel compounds
GB0322510D0 (en) Novel compounds
MX2007006754A (es) Derivados de indenilo y uso de los mismos para el tratamiento de trastornos neurologicos.
PT1853232E (pt) Forma cristalina estável de mesilato de bifeprunox, suas formas de dosagem e métodos para a sua utilização
WO2005097778A8 (en) Tetrahydrobenzazepines as histamine h3 receptor ligands
TW200726763A (en) Novel compound
TW200734324A (en) Therapeutic agents

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)